Clinical-stage biopharmaceutical company developing AAV-mediated gene therapies, particularly for chronic and age-related degenerative ocular diseases
Clinical-stage biopharmaceutical company developing AAV-mediated gene therapies, particularly for chronic and age-related degenerative ocular diseases. It also provides AAV vector development, manufacturing, analytical testing, and CMC support for gene therapy programs.